StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Fennec Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Fennec Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $216.00K, down 37.9% year over year. For fiscal 2025 it was $250.00K, down 18.6% from the year before. Over ten years it grew -0.2% a year on average. The highest annual figure on record is $5.61M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$250.00K-18.6%
FY2024Dec 31, 2024$307.00K+448.2%
FY2023Dec 31, 2023$56.00K-98.4%
FY2022Dec 31, 2022$3.53M-29.1%
FY2021Dec 31, 2021$4.98M-2.4%
FY2020Dec 31, 2020$5.11M-9.0%
FY2019Dec 31, 2019$5.61M+12.0%
FY2018Dec 31, 2018$5.01M+158.7%
FY2017Dec 31, 2017$1.94M+310.2%
FY2016Dec 31, 2016$472.00K+84.4%
FY2015Dec 31, 2015$256.00K-28.3%
FY2014Dec 31, 2014$357.00K-40.2%
FY2013Dec 31, 2013$597.00K-71.2%
FY2012Dec 31, 2012$2.08M+38.9%
FY2011Dec 31, 2011$1.49M+111.0%
FY2010Dec 31, 2010$708.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$118.00K+10.3%
Q1 FY2026Mar 31, 2026$49.00K-47.9%
Q4 FY2025Dec 31, 2025$20.00K-60.0%
Q3 FY2025Sep 30, 2025$29.00K-70.1%
Q2 FY2025Jun 30, 2025$107.00K-31.8%
Q1 FY2025Mar 31, 2025$94.00K+3033.3%
Q4 FY2024Dec 31, 2024$50.00K+56.3%
Q3 FY2024Sep 30, 2024$97.00K+708.3%
Q2 FY2024Jun 30, 2024$157.00K+1862.5%
Q1 FY2024Mar 31, 2024$3.00K-25.0%
Q4 FY2023Dec 31, 2023$32.00K-72.6%
Q3 FY2023Sep 30, 2023$12.00K-98.6%
Q2 FY2023Jun 30, 2023$8.00K-99.3%
Q1 FY2023Mar 31, 2023$4.00K-99.7%
Q4 FY2022Dec 31, 2022$117.00K-77.6%
Q3 FY2022Sep 30, 2022$846.00K-31.9%
Q2 FY2022Jun 30, 2022$1.13M+41.4%
Q1 FY2022Mar 31, 2022$1.44M-40.5%
Q4 FY2021Dec 31, 2021$523.00K-57.2%
Q3 FY2021Sep 30, 2021$1.24M-9.2%
Q2 FY2021Jun 30, 2021$800.00K-28.6%
Q1 FY2021Mar 31, 2021$2.42M+73.4%
Q4 FY2020Dec 31, 2020$1.22M+4.4%
Q3 FY2020Sep 30, 2020$1.37M+72.1%
Q2 FY2020Jun 30, 2020$1.12M-43.1%
Q1 FY2020Mar 31, 2020$1.39M-16.6%
Q4 FY2019Dec 31, 2019$1.17M-32.0%
Q3 FY2019Sep 30, 2019$795.00K-55.8%
Q2 FY2019Jun 30, 2019$1.97M+146.7%
Q1 FY2019Mar 31, 2019$1.67M+142.5%
Q4 FY2018Dec 31, 2018$1.72M+94.5%
Q3 FY2018Sep 30, 2018$1.80M+265.4%
Q2 FY2018Jun 30, 2018$798.00K+139.6%
Q1 FY2018Mar 31, 2018$689.00K+206.2%
Q4 FY2017Dec 31, 2017$886.00K+409.2%
Q3 FY2017Sep 30, 2017$492.00K+339.3%
Q2 FY2017Jun 30, 2017$333.00K–
Q1 FY2017Mar 31, 2017$225.00K–
Q4 FY2016Dec 31, 2016$174.00K–
Q3 FY2016Sep 30, 2016$112.00K–

More Fennec Pharmaceuticals figures

See a number that looks wrong?